These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30544533)

  • 1. Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease.
    Volpato D; Holzgrabe U
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic agonists and the treatment of Alzheimer's disease.
    Messer WS
    Curr Top Med Chem; 2002 Apr; 2(4):353-8. PubMed ID: 11966459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease.
    Kamkwalala AR; Newhouse PA
    Curr Alzheimer Res; 2017; 14(4):377-392. PubMed ID: 27697062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment.
    Lombardo S; Maskos U
    Neuropharmacology; 2015 Sep; 96(Pt B):255-62. PubMed ID: 25514383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
    Messer WS
    J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A
    Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.
    Ahmed T; Zahid S; Mahboob A; Farhat SM
    Curr Neuropharmacol; 2017; 15(4):480-494. PubMed ID: 27012953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.
    Nordberg A; Lundqvist H; Hartvig P; Andersson J; Johansson M; Hellstrŏm-Lindahi E; Långström B
    Dement Geriatr Cogn Disord; 1997; 8(2):78-84. PubMed ID: 9065319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease: Targeting the Cholinergic System.
    Ferreira-Vieira TH; Guimaraes IM; Silva FR; Ribeiro FM
    Curr Neuropharmacol; 2016; 14(1):101-15. PubMed ID: 26813123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.
    Vesey R; Birrell JM; Bolton C; Chipperfield RS; Blackwell AD; Dening TR; Sahakian BJ
    CNS Drugs; 2002; 16(7):485-500. PubMed ID: 12056923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
    Lemière J; Van Gool D; Dom R
    Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of the Cholinergic System and Therapeutic Approaches to Treat Brain Disorders.
    Bertrand D; Wallace TL
    Curr Top Behav Neurosci; 2020; 45():1-28. PubMed ID: 32451956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment.
    Gazova Z; Soukup O; Sepsova V; Siposova K; Drtinova L; Jost P; Spilovska K; Korabecny J; Nepovimova E; Fedunova D; Horak M; Kaniakova M; Wang ZJ; Hamouda AK; Kuca K
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):607-619. PubMed ID: 27865910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors.
    Soukup O; Jun D; Tobin G; Kuca K
    Arch Toxicol; 2013 Apr; 87(4):711-9. PubMed ID: 23179755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of gene expression by muscarinic acetylcholine receptors.
    von der Kammer H; Demiralay C; Andresen B; Albrecht C; Mayhaus M; Nitsch RM
    Biochem Soc Symp; 2001; (67):131-40. PubMed ID: 11447829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.
    Whitehouse PJ; Kellar KJ
    J Neural Transm Suppl; 1987; 24():175-82. PubMed ID: 2960781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for synergistic modulation of early information processing by nicotinic and muscarinic receptors in humans.
    Erskine FF; Ellis JR; Ellis KA; Stuber E; Hogan K; Miller V; Moore E; Bartholomeusz C; Harrison BJ; Lee B; Phan KL; Liley D; Nathan PJ
    Hum Psychopharmacol; 2004 Oct; 19(7):503-9. PubMed ID: 15378678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinic Cholinergic Mechanisms in Alzheimer's Disease.
    Shen J; Wu J
    Int Rev Neurobiol; 2015; 124():275-92. PubMed ID: 26472533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.